Author:
Holst Frederik,Hoivik Erling A.,Gibson William J.,Taylor-Weiner Amaro,Schumacher Steven E.,Asmann Yan W.,Grossmann Patrick,Trovik Jone,Necela Brian M.,Thompson E. Aubrey,Meyerson Matthew,Beroukhim Rameen,Salvesen Helga B.,Cherniack Andrew D.
Abstract
Abstract
The estrogen receptor alpha (ERα) is highly expressed in both endometrial and breast cancers, and represents the most prevalent therapeutic target in breast cancer. However, anti-estrogen therapy has not been shown to be effective in endometrial cancer. Recently it has been shown that hormone-binding domain alterations of ERα in breast cancer contribute to acquired resistance to anti-estrogen therapy. In analyses of genomic data from The Cancer Genome Atlas (TCGA), we observe that endometrial carcinomas manifest recurrent ESR1 gene amplifications that truncate the hormone-binding domain encoding region of ESR1 and are associated with reduced mRNA expression of exons encoding the hormone-binding domain. These findings support a role for hormone-binding alterations of ERα in primary endometrial cancer, with potentially important therapeutic implications.
Publisher
Springer Science and Business Media LLC
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献